Screener
Enliven Therapeutics ELVN Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
FAQ
- What is Enliven Therapeutics's free cash flow?
- Enliven Therapeutics (ELVN) reported free cash flow of -$19.29M in Q1 2026.
- How has Enliven Therapeutics's free cash flow changed year-over-year?
- Enliven Therapeutics's free cash flow increased by 20.1% year-over-year, from -$24.15M to -$19.29M.
- What is the long-term trend for Enliven Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Enliven Therapeutics's free cash flow has grown at a 10.8% compound annual growth rate (CAGR), from -$46.78M to -$70.46M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Enliven Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude